Production (Stage)
Autolus Therapeutics plc
AUTL
$1.54
$0.010.65%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.01M | 10.12M | 10.09M | 10.50M | 10.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.01M | 10.12M | 10.09M | 10.50M | 10.50M |
| Cost of Revenue | 220.82M | 206.81M | 185.83M | 186.14M | 182.76M |
| Gross Profit | -211.81M | -196.69M | -175.74M | -175.64M | -172.26M |
| SG&A Expenses | 121.25M | 109.89M | 91.31M | 74.59M | 63.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 276.28M | 250.91M | 228.29M | 203.56M | 189.40M |
| Operating Income | -267.27M | -240.79M | -218.20M | -193.07M | -178.91M |
| Income Before Tax | -234.37M | -219.14M | -270.19M | -233.98M | -221.28M |
| Income Tax Expenses | 3.76M | 1.53M | 41.00K | -2.00K | -13.00K |
| Earnings from Continuing Operations | -238.13 | -220.66 | -270.23 | -233.98 | -221.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -238.13M | -220.66M | -270.23M | -233.98M | -221.26M |
| EBIT | -267.27M | -240.79M | -218.20M | -193.07M | -178.91M |
| EBITDA | -259.08M | -233.07M | -210.78M | -186.21M | -172.43M |
| EPS Basic | -0.89 | -0.87 | -1.21 | -1.16 | -1.21 |
| Normalized Basic EPS | -0.55 | -0.54 | -0.75 | -0.72 | -0.75 |
| EPS Diluted | -0.89 | -0.87 | -1.21 | -1.16 | -1.21 |
| Normalized Diluted EPS | -0.55 | -0.54 | -0.75 | -0.72 | -0.75 |
| Average Basic Shares Outstanding | 1.06B | 1.02B | 928.38M | 836.28M | 744.11M |
| Average Diluted Shares Outstanding | 1.06B | 1.02B | 928.38M | 836.28M | 744.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |